Japan Long-term Safety for Tiotropium Plus Olodaterol

This study has been completed.
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
First received: February 16, 2012
Last updated: December 18, 2014
Last verified: December 2014

The primary objective of this study is to assess the safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC and olodaterol (delivered by the RESPIMAT Inhaler) in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD).

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: Tiotropium + Olodaterol
Device: Respimat
Drug: Olodaterol
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed-dose Combination (2.5µg / 5µg, 5µg / 5µg ) and Olodaterol (5 µg) Delivered by the RESPIMAT Inhaler in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • All adverse events (including physical examination) until the end of study [ Time Frame: 55 weeks ] [ Designated as safety issue: No ]
  • Vital signs: pulse rate and blood pressure (seated) [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • Routine blood chemistry, haematology and urinalysis [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • 12-lead ECG [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • Time to discontinuation from study drug [ Time Frame: 55 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • FEV1 AUC0-3h [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • Trough FEV1 [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Enrollment: 122
Study Start Date: February 2012
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Tiotropium + Olodaterol (high dose)
Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
Drug: Tiotropium + Olodaterol
Tiotropium and Olodaterol FDC once daily inhalation
Device: Respimat
Respimat inhaler
Olodaterol solution for inhalation - RESPIMAT
Drug: Olodaterol
Olodaterol once daily inhalation
Device: Respimat
Respimat inhaler
Tiotropium + Olodaterol (low dose)
Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
Drug: Tiotropium + Olodaterol
Tiotropium and Olodaterol FDC once daily inhalation
Device: Respimat
Respimat inhaler


Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Diagnosis of chronic obstructive pulmonary disease.
  2. Relatively stable airway obstruction with post FEV1< 80% predicted normal and post FEV1/FVC <70%.
  3. Male or female Japanese patients, 40 years of age or older.
  4. Smoking history of more than 10 pack years.

Exclusion criteria:

  1. Significant disease other than COPD
  2. Clinically relevant abnormal lab values.
  3. History of asthma.
  4. Diagnosis of thyrotoxicosis
  5. Diagnosis of paroxysmal tachycardia
  6. History of myocardial infarction within 1 year of screening visit
  7. Unstable or life-threatening cardiac arrhythmia.
  8. Hospitalization for heart failure within the past year.
  9. Known active tuberculosis.
  10. Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years
  11. History of life-threatening pulmonary obstruction.
  12. History of cystic fibrosis.
  13. Clinically evident bronchiectasis.
  14. History of significant alcohol or drug abuse.
  15. Thoracotomy with pulmonary resection
  16. Oral ß-adrenergics.
  17. Oral corticosteroid medication at unstable doses
  18. Regular use of daytime oxygen therapy for more than one hour per day
  19. Pulmonary rehabilitation program in the six weeks prior to the screening visit
  20. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit
  21. Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA
  22. Pregnant or nursing women.
  23. Women of childbearing potential not using a highly effective method of birth control
  24. Patients who are unable to comply with pulmonary medication restrictions
  25. Patients with narrow-angle glaucoma or micturition disorder due to prostatic hyperplasia etc.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01536262

1237.22.81015 Boehringer Ingelheim Investigational Site
Chiyoda-ku, Tokyo, Japan
1237.22.81023 Boehringer Ingelheim Investigational Site
Chuo-ku, Tokyo, Japan
1237.22.81009 Boehringer Ingelheim Investigational Site
Hamamatu, Shizuoka, Japan
1237.22.81011 Boehringer Ingelheim Investigational Site
Kishiwada, Osaka, Japan
1237.22.81007 Boehringer Ingelheim Investigational Site
Komatsu, Ishikawa, Japan
1237.22.81028 Boehringer Ingelheim Investigational Site
Koriyama, Fukushima, Japan
1237.22.81019 Boehringer Ingelheim Investigational Site
Koto-ku,Tokyo, Japan
1237.22.81021 Boehringer Ingelheim Investigational Site
Kyoto, Kyoto, Japan
1237.22.81014 Boehringer Ingelheim Investigational Site
Minami-ku, Kumamoto, Kumamoto, Japan
1237.22.81017 Boehringer Ingelheim Investigational Site
Morioka, Iwate, Japan
1237.22.81004 Boehringer Ingelheim Investigational Site
Nagaoka, Niigata, Japan
1237.22.81029 Boehringer Ingelheim Investigational Site
Nagasaki, Nagasaki, Japan
1237.22.81027 Boehringer Ingelheim Investigational Site
Osakasayama, Osaka, Japan
1237.22.81008 Boehringer Ingelheim Investigational Site
Saku, Nagano-ken, Japan
1237.22.81025 Boehringer Ingelheim Investigational Site
Sapporo, Hokkaido, Japan
1237.22.81016 Boehringer Ingelheim Investigational Site
Sapporo, Hokkaido, Japan
1237.22.81022 Boehringer Ingelheim Investigational Site
Sapporo, Hokkaido, Japan
1237.22.81001 Boehringer Ingelheim Investigational Site
Sapporo, Hokkaido, Japan
1237.22.81018 Boehringer Ingelheim Investigational Site
Setagaya-ku, Tokyo, Japan
1237.22.81026 Boehringer Ingelheim Investigational Site
Tagajyo,Miyagi, Japan
1237.22.81010 Boehringer Ingelheim Investigational Site
Takatsuki, Osaka, Japan
1237.22.81020 Boehringer Ingelheim Investigational Site
Toyohashi, Aichi, Japan
1237.22.81030 Boehringer Ingelheim Investigational Site
Unzen, Nagasaki, Japan
1237.22.81003 Boehringer Ingelheim Investigational Site
Yokohama,Kanagawa, Japan
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01536262     History of Changes
Other Study ID Numbers: 1237.22
Study First Received: February 16, 2012
Last Updated: December 18, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Disease Attributes
Lung Diseases, Obstructive
Pathologic Processes
Respiratory Tract Diseases
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 01, 2015